Pulse.

a daily field guide to health research that matters

◆ Console

‹ Thu · 29 Oct 2026
Standard addition

IDH2 p.R172 mutation Predicts Superior Outcomes in IDH-mutated Acute Myeloid Leukemia or Myelodysplastic Syndrome patients undergoing Allogeneic Hematopoietic Cell Transplantation: a retrospective study from the Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH-TC)

A specific genetic variant predicted better transplant outcomes and lower relapse rates in acute leukemia patients.

This retrospective multicenter cohort study examined IDH2 p.R172 mutation Predicts Superior Outcomes in IDH-mutated Acute Myeloid Leukemia or Myelodysplastic Syndrome patients undergoing Allogeneic Hematopoietic Cell Transplantation: a retrospective study from the Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH-TC). IDH2 p.R172 was independently associated with no observed relapse and better progression-free and overall survival after transplantation.

What the study was

Study design
Retrospective multicenter cohort study
Population
Adults with IDH-mutated AML or MDS undergoing first allogeneic hematopoietic cell transplantation
Sample size
101 patients
Category
Genomics/Precision Medicine
Maturity
Validated
Journal
Transplantation and cellular therapy

Why it surfaced

Retrospective multicenter cohort study; IDH2 p.R172 was independently associated with no observed relapse and better progression-free and overall survival after transplantation. Score kept conservative because only the PubMed abstract and metadata were reviewed.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.